VisionAir Solutions creates patient-specific airway stents with its 3D-design platform. VisionAir 3D Patient-Specific Stents provide improved stent life, increased time between interventions, and reduced complications for an improved patient quality of life.
VisionAir 3D Stents are personalized by pulmonologists using innovative cloud software (VisionAir 3D Stent Architect). With this unique software a physician simply uploads a patient’s scans and receives a personalized silicone stent within days that fits the patient’s specific anatomy near to perfect. This allows physicians to tailor a 3D Stent to each patient’s unique anatomy to reduce complications caused by poorly-fitting stock silicone stents. Instead of an average stock stent life of 60 days, these patient-specific stents have an average life of years, although the VisionAir stent is clinically approved by the FDA for one year. To see how simple the process is, view the video here
VisionAir stents have broad indications for the treatment of symptomatic central airway obstruction (CAO) in mature individuals that are 22 years of age or older. 3D Stents may be implanted in any location in the airway that a physician can reach with a rigid bronchoscope for implantation. This means that the 3D Stent is unique in that it can be designed to fit carinas distal to the main carina, while current traditional silicone Y-stents have stock diameters, angles, and lengths specifically designed for only the main carina.
Randy Theken, Founder of Theken Companies, said of the acquisition, “I was truly overwhelmed by the technology created by the VisionAir team at Cleveland Clinic. The VisionAir 3D Patient-Specific Stents provide significantly improved stent life and an improved patient quality of life. This is exciting not only for the pulmonary field, but for the potential to apply this technology to other medical devices.”
Thomas Gildea, MD, FCCP, FACP, of Cleveland Clinic and Inventor and Head of the Clinical Advisory Team at VisionAir Solutions, stated, “We are excited to collaborate with Randy Theken and the new VisionAir team. They continue to share our vision of bringing innovative technology to as many patients as possible.” Cleveland Clinic has an equity interest in VisionAir and is entitled to royalty payments and other commercialization revenues from the company for technology developed at Cleveland Clinic. VisionAir is the developer and manufacturer of the stents. Dr. Gildea and others at Cleveland Clinic are inventors and are entitled to royalty payments and other commercialization revenues from the company in accordance with Cleveland Clinic policy.
